CINGCingulate Inc.

CING Stock Price, Valuation & Chart | Cingulate Inc.

Compare

$5.150+0.04 (+0.78%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CING intrinsic value CING calculated fair value vs price

Overview Financials Dividends Ratios

CING Historical price chart

CING Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization69.37M

PE Ratio-1.43

EPS-3.59

Trading Volume83.11K

Today's High/Low5.26/5.11

Dividend Yield0.00

52 Week High/Low11.89/3.16

Shares Outstanding13.47M

CING Financial Statement

CING Analyst ratings

CING Analysis & performance metrics

CING Company profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder.…

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also…

CING Management team

Name

Position

Thomas Dalton

Vice President of Investor & Public Relations

John A. Roberts M.B.A.

Executive Chairman

Jennifer L. Callahan CPACEO

Interim Chief Executive Officer, Senior Vice President, Chief Financial Officer & Secretary

Shane J. Schaffer Pharm.D.CEO

Co-Founder, Chief Executive Officer & Chairman of the Board (Leave of Absence)

Nilay Patel J.D.

Chief Legal Officer

Matthew N. Brams M.D.

Co-Founder, Executive Vice President & Chief Medical Officer

Raul R. Silva M.D.

Co-Founder, Executive Vice President & Chief Science Officer

Name

Position

Thomas Dalton

Vice President of Investor & Public Relations

John A. Roberts M.B.A.

Executive Chairman

Jennifer L. Callahan CPACEO

Interim Chief Executive Officer, Senior Vice President, Chief Financial Officer & Secretary

Shane J. Schaffer Pharm.D.CEO

Co-Founder, Chief Executive Officer & Chairman of the Board (Leave of Absence)

Nilay Patel J.D.

Chief Legal Officer

Matthew N. Brams M.D.

Co-Founder, Executive Vice President & Chief Medical Officer

Raul R. Silva M.D.

Co-Founder, Executive Vice President & Chief Science Officer

Management Team

Thomas Dalton

Vice President of Investor & Public Relations

John A. Roberts M.B.A.

Executive Chairman

Jennifer L. Callahan CPACEO

Interim Chief Executive Officer, Senior Vice President, Chief Financial Officer & Secretary

Shane J. Schaffer Pharm.D.CEO

Co-Founder, Chief Executive Officer & Chairman of the Board (Leave of Absence)

Nilay Patel J.D.

Chief Legal Officer

Matthew N. Brams M.D.

Co-Founder, Executive Vice President & Chief Medical Officer

Raul R. Silva M.D.

Co-Founder, Executive Vice President & Chief Science Officer

Management

Thomas Dalton

Vice President of Investor & Public Relations

John A. Roberts M.B.A.

Executive Chairman

Jennifer L. Callahan CPACEO

Interim Chief Executive Officer, Senior Vice President, Chief Financial Officer & Secretary

Shane J. Schaffer Pharm.D.CEO

Co-Founder, Chief Executive Officer & Chairman of the Board (Leave of Absence)

Nilay Patel J.D.

Chief Legal Officer

Matthew N. Brams M.D.

Co-Founder, Executive Vice President & Chief Medical Officer

Raul R. Silva M.D.

Co-Founder, Executive Vice President & Chief Science Officer

Total 7 executives

CING Frequently asked questions

What is Cingulate Inc. (CING) Stock Price?

Current stock price of Cingulate Inc. (CING) stock is $5.150. The stock price is +0.78% higher in the session. The intraday range can be seen from this page. Volume of Cingulate Inc. (CING) stock is 83.11K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Cingulate Inc. (CING) stock price going up or down today?

The stock price of Cingulate Inc. (CING) can change with earnings, company news, and overall market sentiment. Cingulate Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Cingulate Inc. stock expensive at its current price?

Whether Cingulate Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CING on this page is -1.43. EPS on this page is -3.59. Compare those figures with peers and growth expectations before deciding if the current Cingulate Inc. price is justified.

How has the stock price of Cingulate Inc. (CING) performed historically?

Historical performance for Cingulate Inc. (CING) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CING reacted to past earnings and market events.

Should I buy Cingulate Inc. (CING) stock, at this price?

Buying Cingulate Inc. (CING) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.